GlassScriptPhysician profile
Samuel Mark Shor
NPI 1184611964
$853.99
in general payments reported to CMS, 2019-2025
17 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $104 · 2022: $53.72 · 2023: $197 · 2024: $92.04 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $167.96 | 2020-2025 | |
| Idorsia Pharmaceuticals US INC | $160.62 | 2022-2023 | Quviviq |
| Abbvie INC. | $120.54 | 2019-2023 | Synthroid, Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $64.07 | 2019-2025 | Hyqvia |
| Axsome Therapeutics, INC. | $43.07 | 2024-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $37.32 | 2019-2020 | |
| Exact Sciences Corporation | $33.50 | 2023-2025 | Cologuard Collection Kit |
| Invivyd INC | $30.03 | 2025 | Pemgarda |
| Pfizer INC. | $27.61 | 2019-2023 | |
| Astellas Pharma US INC | $27.44 | 2023 | Veozah |
| Allergan, INC. | $26.57 | 2020 | |
| Amarin Pharma, INC. | $21.86 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $21.55 | 2025 | Lumryz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.93 | 2019 | |
| Aimmune Therapeutics, INC. | $18.37 | 2025 | Zenpep |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $16.84 | 2020 | |
| Acella Pharmaceuticals, LLC | $16.71 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Shor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.